People with glucose levels between normal and diabetic have impaired glucose tolerance (IGT) or insulin resistance. People with impaired glucose tolerance do not have diabetes, but are at high risk for progressing to diabetes. Each year, 1% to 5% of people whose test results show impaired glucose tolerance actually eventually develop diabetes. Weight loss and exercise may help people with impaired glucose tolerance return their glucose levels to normal. In addition, some physicians advocate the use of medications, such as metformin (Glucophage), to help prevent/delay the onset of overt diabetes.
Big pharma are in the early stages of developing their own cell therapy approaches for diabetes. Novo Nordisk, one of the largest providers of diabetes treatments, is bidding for stem cells and an encapsulation device, stating that the first clinical trial could take place in the “next few years.” Sanofi, also a big name in diabetes, is working with the German Evotec in a beta cell replacement therapy for diabetics.
The consumption of commodified connection doesn’t need to require a small fortune, though. In fact, it can’t, by any of the new, woke definitions of wellness. Hoess would like to get Wellspring up to 4,000 people or so, he tells me, in order to keep the price down. I met two seekers who were there on scholarship, and four who had won a ticket through an Instagram giveaway (people actually do win those things). Hoess contrasted his model with smaller events like the Aspen Ideas Festival (which The Atlantic has long been a partner in producing), which tend to be more expensive at least partly due to scale.